A Comparative Study of Self-Vital Measurements and Telemedicine in the Treatment of Hypertension

Hashimoto Shigeatsu0 个研究点目标入组 234 人开始时间: 2023年2月8日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•(1) Men and women between the ages of 40 and 75 at the time consent is obtained
•(2) Patients with persistent hypertension (home systolic blood pressure averaging 135 mmHg or higher for all 5 days, confirmed by blood pressure diary)
•(3) Untreated for more than 4 weeks or prescription has not been changed for more than 4 weeks
•(4) Able to measure blood pressure at home
•(5) Own a smartphone with access to the Telemedies application
•(6) Have written consent

•(1) Patients who cannot measure their blood pressure at home
•(2) Patients who have been diagnosed with heart failure, angina pectoris, or post-myocardial infarction
•(3) Patients with bilateral carotid artery stenosis or main cerebral artery occlusion
•(4) Patients with chronic kidney disease (eGFR < 60 mL/min/1.73 m2) with urine protein negative (< 0.15 g/gCr in urine at any time)
•(5) Pregnant women
•(6) Plasma aldosterone concentration (CLEIA method)/plasma renin activity ratio >= 200 (except for patients diagnosed with idiopathic aldosteronism)
•(7) Patients with secondary hypertension (except for patients diagnosed with idiopathic aldosteronism and patients with primary aldosteronism after treatment for aldosterone-producing adenomas)
•(8) Patients with atrial fibrillation
•(9) Patients with drug dependence or psychiatric disorders
•(10) Patients participating in other clinical trials
•(11) Patients with other serious diseases
•(12) Other patients deemed inappropriate as subjects by the principal investigator.

发起方

Hashimoto Shigeatsu